Compare Heron Therapeutics Inc (HRTX) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs McCormick & Company, Incorporated — how do they compare? Heron Therapeutics Inc trades at $0.33 (market cap $63.41M), while McCormick & Company, Incorporated trades at $53.03 (market cap $14.27B). The key difference: McCormick & Company, Incorporated is far larger — about 225× Heron Therapeutics Inc's market cap, and McCormick & Company, Incorporated pays a 3.61% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | MKC | |
|---|---|---|
Market Cap | $63.41M | $14.27B |
Sector | Health | Consumer Staples |
52-Week High | $1.49 | $72.26 |
52-Week Low | $0.33 | $45.60 |
Enterprise Value | $161.31M | $18.87B |
Dividend Yield | — | 3.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
MKC trades at $52.96, up 1.3% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $59.67 suggesting 13% upside. The company reported Q2 2026 results that beat expectations, driven by the McCormick de Mexico acquisition and margin expansion, with revenue growth of 16.7% year-over-year. The pending $65 billion merger with Unilever's food business represents a transformative opportunity, though integration risks remain.
The outlook is positive, supported by strong profitability metrics, including a 21.91% net income margin and 25.7% ROE, alongside a reasonable valuation with a P/E of 8.81. Key risks include execution of the Unilever deal, competitive pressures in the consumer segment, and potential macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
